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Abstract We describe a 52-year-old female patient who
presented with a 9.5-cm fibrolamellar hepatocellular car-
cinoma (FL-HCC). The patient was initially unsuitable for
surgical resection and therefore underwent transarterial
chemoembolization followed by selective internal radiation
therapy (SIRT) with Yttrium-90 to downsize the tumour.
Following SIRT, the tumour decreased in volume from 350
to 20 cm3 allowing curative (R0) resection with an exten-
ded left hepatectomy and reconstruction of IVC. This is the
first reported case of FL-HCC treated with SIRT in which,
due to the good SIRT response, the patient was downsized
to allow curative resection.
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Introduction
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare
variant of HCC. While the majority (70% of cases) present
with resectable disease, for those who present with unre-
sectable disease (20–30% of cases), there are limited
treatment options with a 5-year survival between 0 and 5%
and median survival of 12 months [1–3]. Those patients
who are able to undergo resection have a 5-year survival
approaching 70% [4]. FL-HCC is not typically responsive
to chemotherapy, and while liver-directed therapies
[transarterial chemoembolization (TACE) and ablation and
selective internal radiation therapy (SIRT)] are evidence-
based treatments for HCC, their role in FL-HCC is poorly
understood [5–8].
Selective internal radiotherapy (SIRT) with Yttrium-90
(Y90) is an intra-arterial-directed therapy for hepatic
malignancy. Small (20–60 microns) microspheres con-
taining Y90, a beta-emitter, are infused into the target liver
arteries in order to deliver a localized brachytherapy effect
[9, 10]. As hepatic tumours are mostly supplied by the
arterial system, the delivery of Y90-coated microspheres
into the liver arteries is preferentially distributed in
tumours, while aiming to spare normal liver parenchyma
which is supplied by the portal venous system. SIRT is a
well-described treatment for traditional HCC, but its use in
FL-HCC has never been reported. We describe the suc-
cessful delivery of SIRT and observe downsizing that
facilitated curative surgical resection in a patient with
biopsy-proven FL-HCC. Given the importance of resection
in the management of FL-HCC, we hope this case adds to
the literature in expanding treatment considerations in this
difficult-to-manage patient group.
& Sebastian Mafeld
sebastian.mafeld@gmail.com
1 Department of Interventional Radiology, Freeman Hospital,
Newcastle upon Tyne NE7 7DN, UK
2 Department of Hepatobiliary Surgery, Freeman Hospital,
Newcastle upon Tyne NE7 7DN, UK
3 Institute of Cellular Medicine, Faculty of Medical Sciences,
Newcastle University, W. Leech Building, M4.143,
Framlington Place, Newcastle upon Tyne NE2 4HH, UK
4 Department of Cellular Pathology, Royal Victoria Infirmary,
Newcastle upon Tyne Hospitals NHS Foundation Trust,
Newcastle upon Tyne NE1 4LP, UK
123
Cardiovasc Intervent Radiol
https://doi.org/10.1007/s00270-018-1903-6
Case
A 52-year-old female presented with a vague history of
upper abdominal discomfort which prompted an ultrasound
scan and subsequently demonstrated a large hepatic mass
lesion. A CT and MRI were performed showing a 9.5-cm
(350 cm3) mass lesion centred in the caudate lobe but
extending into segments 4a, 7 and 8 (Fig. 1). Imaging
features were non-diagnostic. Differential diagnoses
included HCC or focal nodular hyperplasia. Alpha feto-
protein (AFP) (Roche method) was raised at[ 50,000 IU/
ML (normal range\ 10 IU/ML). A laparoscopic biopsy
was performed. Histological assessment revealed a FL-
HCC with a background non-cirrhotic liver with only mild
steatosis (Fig. 4). Due to the central location of the tumour
and its involvement in the three hepatic veins at their
insertion into the inferior vena cava (IVC), following
multidisciplinary discussion the patient was deemed
unresectable.
Treatment with liver-directed therapy in the form of
TACE with doxorubicin-loaded drug-eluting beads was
performed. At initial TACE, the FL-HCC was noted to
have derived parasitic extrahepatic arterial supply from a
phrenic branch arising off the proximal coeliac axis; this
was treated with 75 mg of 100- to 300-micron doxorubicin-
loaded beads (BTG, London, UK). Three weeks later the
patient had a second TACE from branches of the left
hepatic artery with a total dose of 150 mg of doxorubicin-
loaded M1 (70–150 microns) drug-eluting beads (BTG,
London, UK). Follow-up CT demonstrated a partial
response on mRECIST criteria, but stable by RECIST. The
tumour remained unresectable; therefore, following further
multidisciplinary discussion, SIRT with Y90 was recom-
mended to downsize the tumour. On the planning angio-
gram, the parasitic supply from the phrenic branch to the
tumour was embolized and lung shunt fraction determined
by injecting Technetium 99mTc macro-aggregated albumin
into the left and right hepatic arteries. Arterial supply to the
tumour was confirmed by cone-beam CT images obtained
from the right and left hepatic arteries (pre-SIRT proce-
dure). A lung shunt fraction of 7% was calculated and the
patient proceeded to staged (2-month interval) SIRT using
Fig. 1 Coronal contrast-enhanced CT demonstrating a 9.5-cm
(350 cm3) mass lesion centred in the caudate lobe but extending into
segments 4a, 7 and 8
Fig. 2 Seven months post-completion SIRT, contrast-enhanced CT
showing tumour reduction in size to 38 mm and a volume reduction
to 20 cm3 and now deemed suitable for surgical resection
Fig. 3 Axial contrast-enhanced CT post-extended left hepatectomy
with resection and reconstruction of IVC
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TheraSpheres Y90 glass-coated microspheres with
3.45 GBq delivered to the right hepatic artery (15 months
after initial TACE) and 1.18 GBq from the left hepatic
artery (17 months after initial TACE).
Follow-up imaging 2 months after SIRT delivery
showed a tumour volume reduction from 350 cm3 at
baseline to 53 cm3. Imaging performed two months later
showed there had been further reduction to 30 cm3 and
finally at 7-month follow-up, a reduction to 20 cm3
(Fig. 2). AFP also showed a decrease from[ 50,000 at
baseline to 759 IU/ML at six months post-SIRT. Due to the
good response to SIRT, the patient was surgically re-
evaluated and deemed suitable for resection. The tumour
had regressed away from the right hepatic vein. As there
was still involvement of the IVC, an extended left hepa-
tectomy with IVC replacement was planned. This was to be
done with cardiopulmonary bypass to facilitate the
replacement of the IVC at the confluence of the hepatic
veins.
An extended left hepatectomy with resection and
reconstruction of IVC was performed 8 months post-SIRT
(Fig. 3). This required a median sternotomy for car-
diopulmonary bypass via cannulas in the aorta, SVC and
right atrium. The patient was cooled to 28, and circulatory
arrest was established for the lower half of the body by
cross-clamping the descending aorta and IVC. Then, an
extended left hepatectomy with resection and reconstruc-
tion of the IVC was performed using a Dacron graft.
Histological analysis (Fig. 4) of the resected specimen
demonstrated 95% necrosis of the tumour. Only three
microscopic foci of residual viable FL-HCC were present
(Fig. 4). The resection margin was clear (R0). The
Fig. 4 A–F. Liver biopsy of fibrolamellar hepatocellular carcinoma
(FL-HCC): A Solid nests of large tumour cells with abundant
eosinophilic cytoplasm and hyperchromatic or vesicular nuclei and
prominent nucleoli are seen within a lamellar fibrous stroma
(haematoxylin and eosin—H&E, A 910, B 920, C 920). Intra-
cytoplasmic pale bodies (black arrow) are abundant. The FL-HCC
cells are typically positive for HepPar1 (D 920), keratin 7 (E 920)
and CD68 (F 920). G, I Resection specimen following TACE and
SIRT treatment: G, H isolated, less than 2-mm sized foci of residual
viable FL-HCC (H&E 94) surrounded by TACE spheres (black
arrows). I Coagulative tumour necrosis with cholesterol clefts,
pigmented macrophages and TACE spheres (H&E 94)
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background liver was non-cirrhotic with only mild steatosis
but no steatohepatitis.
The patient had a post-operative stay of 67 days during
which she experienced three grade 3a (Clavien-Dindo)
complications including: pleural effusion treated with
thoracocentesis, bile leak managed conservatively with
percutaneous drainage and partial IVC thrombosis man-
aged with therapeutic anticoagulation. The patient was
subsequently discharged with no evidence of recurrence at
2 months of follow-up.
Discussion
The management of FL-HCC poses several challenges due
to its rarity (0.85–16% of all HCCs) and limited treatment
options. FL-HCC classically affects younger patients in the
absence of chronic liver disease, and unlike HCC AFP
levels are typically normal. However, this classic presen-
tation is not always observed with a variation in age at
presentation, and in up to 25% of cases AFP can be ele-
vated [11, 12]. Surgical resection is the only proven cura-
tive treatment method and reflects the current standard of
care [12, 13]. For unresectable FL-HCC, there is no stan-
dard of care, and several management strategies have been
attempted including chemotherapy, ablation, external beam
radiotherapy and intra-arterial treatments [1, 14–17].
Recently, a characteristic DNAJB1–PRKACA fusion
transcript has been reported in FL-HCC that could present
a therapeutic target in future [18].
Intra-arterial treatment with Y90 with SIRT has not
previously been reported for FL-HCC. It is, however, a
theoretically attractive treatment option due to its evolving
evidence base in traditional HCC and also because FL-
HCC may be radiosensitive [5–8, 17, 19]. Y90-loaded
microspheres are small (20–60 microns) and deposit dis-
tally in the arterial system. As a beta-emitter, the Y90-
loaded microspheres have an effective radiotherapy range
of about 2.5 mm and induce cell injury through DNA
damage [10]. While typically considered a salvage therapy,
some patients treated with SIRT can demonstrate a
response which renders them surgical candidates. In this
case, the FL-HCC showed a tumour volume reduction from
350 cm3 at baseline to 20 cm3 7 months post-SIRT. Based
on the reduction in size, the tumour was then felt to be
surgically resectable but would require partial resection
and reconstruction of the IVC. The concept of surgical
resection after SIRT is new, and only small case series
have shown that it is a technically feasible option in highly
selected patients, but never been reported with FL-HCC
[20, 21]. Downsizing and subsequent resection has, how-
ever, been reported following chemotherapy in the treat-
ment of FL-HCC [22].
Resection after SIRT is associated with a high (42–78%)
90-day morbidity, the most common complication being
bile leak [20, 21]. Following resection, three grade 3a or
above (Clavien-Dindo) complications were encountered in
this case, one of which was also a bile leak but was man-
aged with drainage. The resection was able to achieve a R0
margin and should therefore be regarded as curative.
Conclusion
FL-HCC is a rare hepatic neoplasm with limited treatment
options for unresectable cases. This is the first reported use
of SIRT with Y90 in the management of FL-HCC which
resulted in significant tumour size reduction allowing the
patient to undergo curative surgical resection. While this is
an isolated case, SIRT should be a treatment consideration
in the multidisciplinary management of unresectable FL-
HCC.
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